DUBLIN--(BUSINESS WIRE)--Dec. 22, 2014--
plc (NYSE: MNK), a global specialty biopharmaceutical company, will
present at the 33rd Annual J.P. Morgan Healthcare Conference
at the Westin St. Francis on Union Square in San Francisco on Monday,
January 12, 2015. Mark Trudeau, President and Chief Executive Officer of
Mallinckrodt, will represent the company in a session scheduled to begin
at 3 p.m. Pacific/6 p.m. Eastern.
Individuals who cannot attend the meeting in person can find webcast
information on Mallinckrodt’s Investor
Relations website or at: http://mallinckrodt.com/investor_relations.
A replay will also be available following the meeting.
Mallinckrodt is a global specialty biopharmaceutical and medical imaging
business that develops, manufactures, markets and distributes specialty
pharmaceutical products and medical imaging agents. Areas of focus
include therapeutic drugs for autoimmune and rare disease specialty
areas like neurology, rheumatology, nephrology and pulmonology along
with analgesics and central nervous system drugs for prescribing by
office- and hospital-based physicians. The company's core strengths
include the acquisition and management of highly regulated raw
materials; deep regulatory expertise; and specialized chemistry,
formulation and manufacturing capabilities. The company's Specialty
Pharmaceuticals segment includes branded and specialty generic drugs and
active pharmaceutical ingredients, and the Global Medical Imaging
segment includes contrast media and nuclear imaging agents. Mallinckrodt
has more than 5,500 employees worldwide and a commercial presence in
roughly 65 countries. The company's fiscal 2014 revenue totaled $2.54
billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Rhonda Sciarra, 314-654-8618
Senior Vice President, Communications
Vice President, Investor Relations